

Regimen Reference Order – LEUK – PONATinib

ARIA: LEUK - [PONATinib]

Planned Course: Once daily until disease progression or unacceptable toxicity
Indication for Use: Chronic Myelogenous Leukemia OR
 Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Proceed with treatment if:

- *ANC equal to or greater than $1 \times 10^9/L$*
- *Platelets equal to or greater than $50 \times 10^9/L$*
- *AST/ALT less than 2.5 times upper limit of normal*
- *Total Bilirubin less than 1.5 times upper limit of normal*
- *Lipase less than 1.5 times upper limit normal*
- *Prothrombin time less than 1.5 times upper limit of normal*
- ❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Treatment Regimen – LEUK - PONATinib

Drug	Dose	CCMB Administration Guideline
PONATinib	45 mg	Orally once daily (Self-administered at home)

REQUIRED MONITORING

- Baseline EKG and LVEF, and at 3 months after initiation and clinically indicated thereafter
- Before starting treatment with PONATinib, the cardiovascular status of the patient will be assessed by prescribing physician
- Blood pressure monitoring prior to start of treatment and every 2 weeks for 3 months and then as clinically indicated
- CBC, AST, ALT, total bilirubin, alkaline phosphatase, lipase, serum creatinine, uric acid, calcium, albumin, phosphate, prothrombin time prior to start of treatment and every 2 weeks for 3 months and then as clinically indicated

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
acetylsalicylic acid	81 mg	Orally once daily (Self-administered at home)
allopurinol	300 mg	Orally once daily (Self-administered at home – for patients at risk of tumor lysis syndrome)

DISCHARGE INSTRUCTIONS

- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- CancerCare Manitoba Pharmacy will be the only pharmacy in Manitoba that will dispense PONATinib due to the restricted distribution program
- Only prescribers registered under the Iclusig Distribution Program will be able to prescribe PONATinib
- Consideration should be given to lower the PONATinib dose to 15 mg once daily once major cytogenetic response achieved in patients with chronic phase CML
- Vigilance for symptoms suggestive of arterial thrombosis
- Available tablet strength: 15mg and 45mg tablets